Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: a longitudinal T2 relaxometry pilot study

Stephen J Wood; Luca Cocchi; Tina-Marie Proffitt; Mirabel McConchie; Graeme D Jackson; Tsutomu Takahashi; Christos Pantelis; Patrick D McGorry; Gregor E Berger

doi:10.1016/j.pscychresns.2009.12.003

Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: a longitudinal T2 relaxometry pilot study

Psychiatry Res. 2010 May 30;182(2):180-2. doi: 10.1016/j.pscychresns.2009.12.003. Epub 2010 Apr 21.

Authors

Stephen J Wood¹, Luca Cocchi, Tina-Marie Proffitt, Mirabel McConchie, Graeme D Jackson, Tsutomu Takahashi, Christos Pantelis, Patrick D McGorry, Gregor E Berger

Affiliation

¹ Melbourne Neuropsychiatry Centre, University of Melbourne, Australia. [email protected]

PMID: 20413278
DOI: 10.1016/j.pscychresns.2009.12.003

Abstract

We used magnetic resonance imaging to examine the effect of ethyl-eicosapentaenoic acid (E-EPA) on hippocampal T(2) relaxation time in first episode psychosis patients at baseline and after 12 weeks of follow-up. There was an increase in T(2) in the placebo group but not in the E-EPA group, suggesting a neuroprotective effect of E-EPA treatment. In addition, the smaller the increase in T(2), the greater the improvement in negative symptoms.

Publication types

Clinical Trial
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Analysis of Variance
Double-Blind Method
Eicosapentaenoic Acid / analogs & derivatives*
Eicosapentaenoic Acid / therapeutic use
Female
Hippocampus / drug effects
Humans
Longitudinal Studies
Male
Neuroprotective Agents / therapeutic use*
Pilot Projects
Psychotic Disorders / drug therapy*
Psychotic Disorders / pathology
Statistics as Topic
Young Adult

Substances

Neuroprotective Agents
eicosapentaenoic acid ethyl ester
Eicosapentaenoic Acid